# Ipamorelin Dosing in Research: Doses, Routes, and Half-Life Context > Ipamorelin dosing as studied in research only: the doses and routes used in human PK, the failed trial, and rodent work — third person, no human recommendation. Fully cited. ## Read this first This page describes **Ipamorelin** doses only as they appear in published research — what was given to which species, by which route, for how long. It is not a protocol and not a recommendation. There is no approved human dose of ipamorelin, because the compound is not approved [3]. The community combination protocols you may have seen (paired with CJC-1295, given under the skin) have **no** peer-reviewed human dosing basis and are described here as anecdotal, not recommended. Where a number appears below, it is attached to its study. Nothing on this page tells anyone to take anything. ## Doses used in human studies Two human datasets define the studied range. In the PK/PD study, healthy male volunteers received single 15-minute IV infusions at 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, producing dose-proportional kinetics [2]. In the only efficacy trial, bowel-resection patients received 0.03 mg/kg IV twice daily for up to 7 days — a regimen that missed its primary endpoint [3]. Both were intravenous and clinic-administered. Neither establishes a self-administration dose, and the dominant real-world route (subcutaneous) has no published human PK characterization at all [3]. ## Doses used in animal studies Rodent work spans a range. Subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily, 15 days) dose-dependently increased rat longitudinal bone growth [4]. A continuous-infusion bone-mineral study used 0.5 mg/kg/day via osmotic minipump over 12 weeks. Rat postoperative-ileus work used 0.1–1 mg/kg IV repeated four times daily. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneal [5]. These are species- and model-specific research doses; none translates to a human regimen. ## Routes studied Ipamorelin has been administered intravenously (human PK and clinical trials; rodent efficacy) [2][3], subcutaneously (rodent bone and body-composition studies, and the dominant route in community use) [4], intranasally (rodent PK, ~20% bioavailability), and intraperitoneally (rodent/ferret efficacy) [5]. Oral dosing applies only to engineered ipamorelin-derived analogs such as NN703 (~30% oral bioavailability in dogs) [7] — ipamorelin itself is not orally bioavailable. The route matters for kinetics and for any safety interpretation: the human half-life figures come specifically from IV dosing [2]. ## Half-life and timing In healthy human volunteers the terminal half-life is approximately 2 hours (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg; the GH response is a single discrete pulse peaking about 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance is roughly 5-fold lower than GHRP-6 [1]. The full time-in-system breakdown — and why "2-hour half-life" does not mean "out of your system in 2 hours" — is on the dedicated [half-life](/half-life) page. ## How much cjc-1295 ipamorelin should i take There is no answer to this that any published human trial supports — and this page does not provide a dose. The CJC-1295 + ipamorelin combination has never been tested for dosing in a controlled human study; its support is single-agent pharmacology plus animal work, and a 2026 review that found a muscle effect in mice explicitly noted evidence is limited to animal studies [18]. Community subcutaneous "stack" regimens exist but have no peer-reviewed human dosing basis and are anecdotal, not recommended [3]. Anyone weighing this should understand that no validated dose, schedule, or safety-monitoring framework exists for the combination in humans [17]. ## How to reconstitute cjc-1295 ipamorelin 5mg This is the most-searched handling question, and the honest answer is a research-handling description, not a preparation instruction for use. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and in the research-supply literature is reconstituted with bacteriostatic water for handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and the "5mg" figure is a vial-labeling convention from suppliers, not a validated dose. No human dosing is implied or provided. --- A tolerability-first read of the ipamorelin record — the failed Phase 2 endpoint, the two-hour half-life, and the class cardiotoxicity signal logged before anything flattering, every figure carried back to the study that measured it; a reference console, never a clinic, a prescriber, or a store.